Skip navigation

Academic drug discovery: Current status and prospects

Academic drug discovery: Current status and prospects

Everett, Jeremy R. ORCID: 0000-0003-1550-4482 (2015) Academic drug discovery: Current status and prospects. Expert Opinion on Drug Discovery, 10 (9). pp. 937-944. ISSN 1746-0441 (Print), 1746-045X (Online) (doi:10.1517/17460441.2015.1059816)

[img]
Preview
PDF (Author's Accepted Manuscript)
14880_Everett_Academic drug discover (AAM) 2015.pdf - Accepted Version

Download (320kB) | Preview

Abstract

Introduction.
The contraction in pharmaceutical drug discovery operations in the past decade has been counter-balanced by a significant rise in the number of academic drug discovery groups. In addition, pharmaceutical companies that used to operate in completely independent, vertically-integrated operations for drug discovery are now collaborating more with each other, and with academic groups. We are in a new era of drug discovery.

Areas Covered.
This review provides an overview of the current status of academic drug discovery groups, their achievements and the challenges they face,, together with perspectives on ways to achieve improved outcomes.

Expert Opinion.
Academic groups have made important contributions to drug discovery, from its earliest days and continue to do so today. However, modern drug discovery and development is exceedingly complex, and has high failure rates, principally because human biology is complex and poorly understood. Academic drug discovery groups need to play to their strengths and not just copy what has gone before. However, there are lessons to be learnt from the experiences of the industrial drug discoverers and four areas are highlighted for attention: (i) increased validation of targets, (ii) elimination of false hits from HTS, (iii) increasing the quality of molecular probes and (iv) investing in a high quality informatics infrastructure.

Item Type: Article
Additional Information: This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Opinion on Drug Discovery on June 19, 2015, available online: http://www.tandfonline.com/10.1517/17460441.2015.1059816
Uncontrolled Keywords: Academic, Drug discovery, High throughput screening, HTS, Molecular probes, Pan-assay interference compounds (PAINS)
Faculty / Department / Research Group: Faculty of Engineering & Science > Department of Pharmaceutical, Chemical & Environmental Sciences
Last Modified: 17 Oct 2016 09:14
Selected for GREAT 2016: None
Selected for GREAT 2017: None
Selected for GREAT 2018: None
URI: http://gala.gre.ac.uk/id/eprint/14880

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics